文章核心观点 华尔街分析师对欧加农（OGN）即将发布的季度财报进行预测，包括每股收益、营收等指标，并给出特定关键指标的平均估计，同时提及公司股价过去一个月表现及Zacks排名情况 [1][4][9] 季度财报预期 - 预计每股收益1.06美元，同比下降19.1% [1] - 预计营收16.3亿美元，同比增长1.1% [1] - 过去30天，本季度共识每股收益预估上调2.5%至当前水平 [1] 关键指标平均估计 女性健康业务 - “Revenue - Women's Health - Nexplanon/Implanon NXT”预计达2.1897亿美元，同比增长2.3% [4] - “Revenue - Women's Health - NuvaRing”预计达3737万美元，同比下降6.6% [5] - “Revenue - Women's Health - Follistim AQ”预计达6488万美元，同比下降7.3% [5] - “Revenue - Women's Health - U.S. - Nexplanon/Implanon NXT”预计达1.5574亿美元，同比下降2.1% [5] - “Revenue - Women's Health - U.S. - NuvaRing”预计达1618万美元，同比下降4.8% [6] - “Revenue - Women's Health - U.S. - Follistim AQ”预计达2770万美元，同比增长6.5% [6] 生物仿制药业务 - “Revenue - Biosimilars Total”预计达1.7639亿美元，同比增长30.7% [4] 地理区域营收 - “Geographic Revenue - U.S.”预计达4.0979亿美元，同比增长10.5% [6] 成熟品牌国际业务 - “Revenue - Established Brands - Int'l - Non - Opioid Pain, Bone and Dermatology - Other”预计达7473万美元，同比增长11.5% [7] - “Revenue - Established Brands - Int'l - Non - Opioid Pain, Bone and Dermatology - Diprospan”预计达2396万美元，同比增长99.7% [7] - “Revenue - Established Brands - Int'l - Non - Opioid Pain, Bone and Dermatology - Fosamax”预计达4307万美元，同比下降2.1% [8] - “Revenue - Established Brands - Int'l - Non - Opioid Pain, Bone and Dermatology - Arcoxia”预计达6604万美元，同比下降8.3% [8] 股价表现与排名 - 过去一个月，欧加农股票回报率为7.6%，而Zacks标准普尔500综合指数变化为1.1% [8] - 基于Zacks排名3（持有），欧加农未来表现可能与整体市场一致 [9]